CS:EURONEXT PARISAXA SA Analysis
Data as of 2026-05-20 - not real-time
$114.35
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Technical momentum is firmly bullish – the price sits well above the 20‑day, 50‑day and 200‑day SMAs, the MACD line is above its signal, and the histogram is positive. However, the RSI is in the high‑70s, signaling overbought conditions as the stock nears its 52‑week resistance around $119.
Fundamentally, Cisco delivers solid growth with 12% revenue expansion, healthy gross and operating margins, and a robust free cash flow pipeline that comfortably covers its 55% dividend payout. The forward PE of roughly 24 suggests earnings are accelerating, yet the DCF‑derived fair value near $48 indicates the market price is substantially premium, making the stock appear overvalued despite an attractive dividend yield of 1.46% and a stable balance sheet.
Fundamentally, Cisco delivers solid growth with 12% revenue expansion, healthy gross and operating margins, and a robust free cash flow pipeline that comfortably covers its 55% dividend payout. The forward PE of roughly 24 suggests earnings are accelerating, yet the DCF‑derived fair value near $48 indicates the market price is substantially premium, making the stock appear overvalued despite an attractive dividend yield of 1.46% and a stable balance sheet.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish MACD and price above key moving averages
- RSI in overbought territory near resistance
- Increasing volume supporting the current trend
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- 12% revenue growth and improving operating margins
- Forward PE compression to ~24 versus trailing 38
- Sustainable dividend payout with strong cash flow
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Significant valuation premium versus DCF fair value
- Stable cash generation and industry leadership
- Long‑term demand for networking and security solutions
Key Metrics & Analysis
Financial Health
Revenue Growth12.00%
Profit Margin19.68%
P/E Ratio38.1
ROE25.23%
ROA7.33%
Debt/Equity64.06
P/B Ratio9.2
Op. Cash Flow$13.0B
Free Cash Flow$9.7B
Industry P/E38.8
Technical Analysis
TrendBullish
RSI76.8
Support$85.78
Resistance$119.39
MA 20$98.76
MA 50$88.24
MA 200$77.37
MACDBullish
VolumeIncreasing
Fear & Greed Index90.29
Valuation
Fair Value$48.22
Target Price$122.87
Upside/Downside7.45%
GradeOvervalued
TypeGrowth
Dividend Yield1.46%
Risk Assessment
Beta0.95
Volatility44.44%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.